Methotrexate Biodim (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This inhibition reduces the production of nucleotides needed for DNA replication, thereby limiting the proliferation of rapidly dividing cells such as immune cells and cancer cells.

The specific dose of Methotrexate Biodim is determined by the prescribing clinician based on the individual patient's condition, weight, renal function, and treatment goals. Dosage regimens vary widely across the different approved indications.

Methotrexate is classified as teratogenic and is contraindicated during pregnancy. Women of child‑bearing potential should use effective contraception. Breastfeeding is also not recommended while receiving methotrexate because the drug can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Methotrexate is a cornerstone antimetabolite with a broad therapeutic range, whereas alternatives like pemetrexed or cytarabine may be used for specific cancers. Methotrexate’s long‑standing clinical experience, oral and injectable formulations, and cost‑effectiveness make it a frequently chosen option, though individual patient factors dictate the best choice.

Methotrexate Biodim should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the container to maintain stability.

The product is supplied as a sterile solution for injection and can be given via intra‑arterial, intradiscal, or intramuscular routes, depending on the clinical indication and physician’s judgment. Administration is performed by qualified healthcare professionals under aseptic conditions.

Serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity or liver fibrosis with long‑term use, pulmonary toxicity such as interstitial pneumonitis, and nephrotoxicity. Prompt monitoring of blood counts and organ function is essential to detect these complications early.

Methotrexate Biodim is contraindicated in patients with significant hepatic or renal impairment, active infections, known hypersensitivity to methotrexate, and in pregnant or breastfeeding women. It should also be avoided in individuals with severe immunodeficiency unless closely supervised.